Author:
Zhang Ruiyi,Yong V. Wee,Xue Mengzhou
Abstract
Intracerebral hemorrhage (ICH) is an important subtype of stroke with an unsatisfactory prognosis of high mortality and disability. Although many pre-clinical studies and clinical trials have been performed in the past decades, effective therapy that meaningfully improve prognosis and outcomes of ICH patients is still lacking. An active area of research is towards alleviating secondary brain injury after ICH through neuroprotective pharmaceuticals and in which minocycline is a promising candidate. Here, we will first discuss new insights into the protective mechanisms of minocycline for ICH including reducing iron-related toxicity, maintenance of blood-brain barrier, and alleviating different types of cell death from preclinical data, then consider its shortcomings. Finally, we will review clinical trial perspectives for minocycline in ICH. We hope that this summary and discussion about updated information on minocycline as a viable treatment for ICH can facilitate further investigations.
Subject
Immunology,Immunology and Allergy
Reference192 articles.
1. Intracerebral Haemorrhage: Current Approaches to Acute Management;Cordonnier;Lancet,2018
2. Intracerebral Hemorrhage in Translational Research;Zhang;Brain Hemorrhages,2020
3. Clinical Neurorestorative Therapeutic Guideline for Brainstem Hemorrhage (2020 China Version);Chen;J Neurorestoratology,2021
4. Incidence, Case Fatality, and Functional Outcome of Intracerebral Haemorrhage Over Time, According to Age, Sex, and Ethnic Origin: A Systematic Review and Meta-Analysis;Van Asch;Lancet Neurol,2010
5. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update;An;J Stroke,2017
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献